ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1378

Validity of Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients with Early Spondyloarthritis

Cruz Fernández-Espartero1, Eugenio De Miguel2, Milena Gobbo3, Carmen Martínez4, Miguel A. Descalzo4, Estíbaliz Loza Sr.5 and Esperanza Group6, 1Servicio de Reumatología, Hospital Universitario de Móstoles, Madrid, Spain, 2Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 3Research Unit, Spanish Society of Rheumatology., Madrid, Spain, 4Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 5Research Unit. Sociedad Española de Reumatología, Madrid, Spain, 6Madrid

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Recently, a Working Group of the SpondyloArtrhitis International Society (ASAS) has proposed a composite disease activity score, the Ankylosing Spondylitis Disease Activity Score (ASDAS), for patients with ankylosing spondylitis (AS), for improved and feasible measures of disease activity and treatment response in patients with spondyloarthritis (SpA).

Objective: To evaluate the validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) as clinical tool for measurement of disease activity in early spondyloarthritis (SpA) in comparison with conventional clinical measures of disease activity. To assess the discriminative ability and correlation of the ASDAS and Bath Ankylosing Spondylitis Activity Disease Activity Index (BASDAI) with disease activity in early SpA.

Methods:

Patients with early SpA were selected from ESPeranza database (n=676). To test concurrent validity of the indices, correlations of the two indices with activity variables were calculated in ESPeranza database. Patients were categorised into high and low disease activity states based on patient and physician global assessment scores and physician´s decision to start on a disease-modifying anti-rheumatic drug or tumour necrosis factor blocker. Discriminatory ability of the indices was compared using the approach of standardised mean difference between subgroups of patients with high vs low disease activity.

Results:

ASDAS-B and C showed good correlation with BASDAI (0.79, 0.74, p<0.001). Both scores correlated well with disease activity as reflected by the patient global assessment (BASDAI 0.71, ASDAS-B 0.70, ASDAS-C 0.70, p <0.001) and the physician global score (r=0.44 for BASDAI, r=0.46 for ASDAS-B, r=0.47 for ASDAS-C, p <0.001). CRP and ESR showed poor correlation with patient- and physician-derived disease activity scores. ASDAS and BASDAI scores show good and moderate discriminative ability with different constructs of disease activity.

Conclusion:

ASDAS is a disease activity index valid in early Spa. ASDAS and BASDAI scores show good and moderate discriminative ability and correlation with different constructs of disease activity. In early Spa, ASDAS showed a slight superiority to BASDAI in its ability to discriminate between high and low disease activity states.


Disclosure:

C. Fernández-Espartero,
None;

E. De Miguel,
None;

M. Gobbo,
None;

C. Martínez,
None;

M. A. Descalzo,
None;

E. Loza Sr.,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validity-of-ankylosing-spondylitis-disease-activity-score-asdas-in-patients-with-early-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology